Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BDTX
stocks logo

BDTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.171
-38.78%
--
--
0.035
-96.43%
--
--
-0.182
-4.38%
Estimates Revision
The market is revising No Change the revenue expectations for Black Diamond Therapeutics, Inc. (BDTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -7.82%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+28.91%
In Past 3 Month
Stock Price
Go Down
down Image
-7.82%
In Past 3 Month
Wall Street analysts forecast BDTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDTX is 8.67 USD with a low forecast of 6.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast BDTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDTX is 8.67 USD with a low forecast of 6.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.710
sliders
Low
6.00
Averages
8.67
High
11.00
Current: 2.710
sliders
Low
6.00
Averages
8.67
High
11.00
Guggenheim
Brad Canino
Buy -> Neutral
downgrade
2025-12-03
New
Reason
Guggenheim
Brad Canino
Price Target
2025-12-03
New
downgrade
Buy -> Neutral
Reason
Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics to Neutral from Buy.
Guggenheim
Brad Canino
Buy -> Neutral
downgrade
2025-12-03
New
Reason
Guggenheim
Brad Canino
Price Target
2025-12-03
New
downgrade
Buy -> Neutral
Reason
Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics to Neutral from Buy without a price target. While the headline overall response rate in the silevertinib 1L non-classical EGFRm phase 2 trial is "competitive," there was very high toxicity and there are questions around potential durability, the analyst tells investors in a research note. The firm sees risk to the 2Q26 progression free survival catalyst and Phase 3 start up execution.
Piper Sandler
Overweight
initiated
$9
2025-11-17
Reason
Piper Sandler
Price Target
$9
2025-11-17
initiated
Overweight
Reason
Piper Sandler assumed coverage of Black Diamond Therapeutics with an Overweight rating and $9 price target. Black Diamond is advancing lead asset silevertinib, a "potentially best-in-class" fourth generation EGFR inhibitor for treatment of non-small cell lung cancer and glioblastoma, the analyst tells investors. The less than $100M enterprise value reflected in shares ahead of multiple clinically de-risking and value creating catalysts over the next 12 months "offers an attractive entry point," the analyst contends.
Stifel
Laura Prendergast
initiated
$8
2025-10-15
Reason
Stifel
Laura Prendergast
Price Target
$8
2025-10-15
initiated
Reason
Stifel analyst Laura Prendergast resumed coverage of Black Diamond Therapeutics with a Buy rating and $8 price target. The firm says the company's silevertinib "checks all the main boxes" to be successful in non-small cell lung cancer. However, the drug has a "tricky path forward" that will likely require a partnership, the analyst tells investors in a research note. Stifel sees the upcoming Phase 2 data as "true make-or-break catalysts for the company."
Freedom Capital
NULL -> Buy
initiated
$6
2025-09-30
Reason
Freedom Capital
Price Target
$6
2025-09-30
initiated
NULL -> Buy
Reason
Freedom Capital initiated coverage of Black Diamond Therapeutics with a Buy rating and $6 price target. Lead program silevertinib has already delivered "encouraging" preliminary efficacy in Phase 2 development in non- small-cell lung cancer, says the analyst, who views Black Diamond as "well positioned to establish a foothold in the highly competitive precision oncology landscape."
Guggenheim
Buy
initiated
$8
2025-09-04
Reason
Guggenheim
Price Target
$8
2025-09-04
initiated
Buy
Reason
Guggenheim initiated coverage of Black Diamond Therapeutics with a Buy rating and $8 price target. The firm believes the company's silevertinib could surpass expectations with its second half of 2025 readout. Black Diamond has a "legitimate claim to have the most rationally designed" EGFR inhibitor for the "sizable" non-classical EGFRm non-small cell lung cancer population, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Black Diamond Therapeutics Inc (BDTX.O) is -4.89, compared to its 5-year average forward P/E of -3.47. For a more detailed relative valuation and DCF analysis to assess Black Diamond Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.47
Current PE
-4.89
Overvalued PE
1.11
Undervalued PE
-8.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.70
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.37
Undervalued EV/EBITDA
-2.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.86
Current PS
0.00
Overvalued PS
4.83
Undervalued PS
-3.11
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BDTX News & Events

Events Timeline

(ET)
2025-12-03
07:10:00
Black Diamond Therapeutics Announces Phase 2 Trial Data for Silevertinib in NSCLC
select
2025-11-06 (ET)
2025-11-06
07:33:50
Black Diamond Therapeutics projects funding to last through the fourth quarter of 2027.
select
2025-11-06
07:33:37
Black Diamond Therapeutics Announces Q3 Earnings Per Share of 15 Cents, Below Consensus Estimate of 23 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04Benzinga
PinnedBlack Diamond's Lung Cancer Treatment Demonstrates 60% Response Rate in Phase 2 Results

  • Phase 2 Trial Results: Black Diamond Therapeutics reported topline data from its Phase 2 trial of silevertinib in non-small cell lung cancer patients, showing a 60% objective response rate and 86% CNS response rate, with no new safety signals observed.

  • Stock Performance: Following the trial results, BDTX stock experienced a significant decline of 23.77%, trading at $2.62.

  • Future Plans: The company plans to present updated trial results in 2026 and is also set to initiate a randomized Phase 2 trial for glioblastoma patients in the first half of 2026.

  • Financial Outlook: Black Diamond has approximately $135.5 million in cash and investments, which it believes will cover operating expenses into the second half of 2028.

[object Object]
Preview
9.0
12-03NASDAQ.COM
PinnedBlack Diamond to Showcase Phase 2 Results of Silevertinib for Non-Small Cell Lung Cancer Today

  • Webcast Presentation: Black Diamond Therapeutics will host a webcast on December 3, 2025, to present results from its Phase 2 trial of silevertinib in non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations, including objective response rates and treatment duration data from 43 patients.

  • Clinical Trial Progress: Silevertinib is being evaluated in three clinical settings: first-line NSCLC, second/third-line NSCLC in C797S+ patients, and glioblastoma, with key data expected in the first half of 2026.

  • FDA Designation: The second/third-line NSCLC study has received FDA Fast Track designation, highlighting its potential to meet significant medical needs, while the company plans to seek FDA feedback on registration for the first-line NSCLC trial.

  • Financial Status: As of the end of Q3 2025, Black Diamond Therapeutics reported $135.5 million in cash and investments, projected to fund operations through Q4 2027, despite a recent stock price decline to $3.45.

[object Object]
Preview
9.0
12-03Newsfilter
PinnedBlack Diamond Therapeutics to Present Phase 2 Trial Results on December 3, 2025
  • Clinical Trial Update: Black Diamond Therapeutics will present results from its Phase 2 clinical trial of silevertinib during a webcast on December 3, 2025, which may influence investor confidence regarding the company's future developments.
  • Therapeutic Innovation: Silevertinib is a fourth-generation EGFR inhibitor targeting EGFR-mutant non-small cell lung cancer and glioblastoma, designed to overcome resistance and minimize toxicity, showcasing the company's cutting-edge position in cancer treatment.
  • Information Transparency: The webcast will be accessible via the Investors section of the company's website, with a replay available post-event, ensuring investors can timely access critical clinical data and company updates.
  • Market Positioning: Black Diamond Therapeutics focuses on developing therapies targeting genetically defined tumors, indicating its strategy to seek a differentiated competitive advantage in the rapidly evolving oncology market, potentially attracting more investors interested in its innovative treatments.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Black Diamond Therapeutics Inc (BDTX) stock price today?

The current price of BDTX is 2.71 USD — it has increased 0.74 % in the last trading day.

arrow icon

What is Black Diamond Therapeutics Inc (BDTX)'s business?

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

arrow icon

What is the price predicton of BDTX Stock?

Wall Street analysts forecast BDTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDTX is 8.67 USD with a low forecast of 6.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Black Diamond Therapeutics Inc (BDTX)'s revenue for the last quarter?

Black Diamond Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Black Diamond Therapeutics Inc (BDTX)'s earnings per share (EPS) for the last quarter?

Black Diamond Therapeutics Inc. EPS for the last quarter amounts to -0.15 USD, decreased -46.43 % YoY.

arrow icon

What changes have occurred in the market's expectations for Black Diamond Therapeutics Inc (BDTX)'s fundamentals?

The market is revising No Change the revenue expectations for Black Diamond Therapeutics, Inc. (BDTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -7.82%.
arrow icon

How many employees does Black Diamond Therapeutics Inc (BDTX). have?

Black Diamond Therapeutics Inc (BDTX) has 24 emplpoyees as of December 05 2025.

arrow icon

What is Black Diamond Therapeutics Inc (BDTX) market cap?

Today BDTX has the market capitalization of 153.83M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free